Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Articles|October 1, 2002
Newer markers may improve on PSA's shortcomings
Q What is the current state of prostate cancer markers?With prostate cancer, we are fortunate in that it has the very best markeror combination of markers for any cancer that I'm aware of, short of skincancer where visual markers are quite good. PSA's performance for predictinglocalized prostate cancer probably exceeds the performance of other cancermarkers, such as CA125 for ovarian cancer, CEA for colon cancer, and someof the genetic markers for breast cancer.
Advertisement
Advertisement
Related to this article
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
5